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Abstract 
 
Against the background of certain progress in global health, pharmaceutical industry is becoming a vital mechanism of effective 
medicines production. At the same time, being a socially-oriented unit of the world economy, the pharmaceutical market at this 
moment is characterized by particularly high degree of commercialization. Taking this fact into account, the authors aim to 
search for sufficient answers to the key question - whether pharmaceutical market solves global health problems or exists for 
the sake of pharmaceutical companies’ profits maximizing. According to the results both the fact of uneven distribution of drugs 
in the context of developed and developing countries and its causes were established. It is supposed that the economical policy 
of largest pharmaceutical manufacturers is deliberately based on keeping shipments of innovative drugs in developing 
countries in static regime. The main conclusion of the pharmaceutical market ineffectiveness at the present stage was obtained 
by a preliminary analysis of data array using IBM SPSS Statistics 19. 
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1. Introduction 
 
The pharmaceutical market as a set of its enterprises and consumers is becoming one of the most important elements of 
the global economy’s “ecosystem”. Today trends of life expectancy growth and all-round formation of conditions for 
successful economic development depend on investment into human capital. Here we may confidently claim that the 
human capital is up to the health services on the one hand, and the level of its structural parts development on the other 
one. It means that the pharmaceutical market as a mechanism for vital medicine drugs reproduction stimulates social and 
economic development of any nation. Thus, the study of trends occurring in the global pharmaceutical market is the key 
to successful reorientation of the national pharmaceutical sector and, by and large, is a matter of national security. Now 
we may confirm that this study is beneficial to the health and social policy government bodies and its structural units of 
developing countries passing through the era of innovational transformation. 
Recognizing the progress in global health made by the international community over the past 20 years (in 
particular, the reduction of child mortality by 2 times for the period from 2005 to 2010; reducing maternal mortality from 
543.000 in 1990 to 287.000 in 2010; a 50%-decreasing in mortality from malaria and 15%-decreasing in mortality from 
HIV (IMS Healthcare, 2013), it is impossible to miss the huge pharmaceutical industry contribution. Primarily, the 
pharmaceutical research industry plays a unique role in the drugs and vaccines extraction needed for diseases 
prevention and treatment. We should realize, that the main endowment, which pharmaceutical sector brings to the public 
health services is providing of fundamental researches in the field of innovative therapies. Herewith, success of all the 
investigations is based on continuous innovation process focused both on prevention, treatment of prevalent, complex 
and “neglected” diseases, and medicines improvement. It means that the pharmaceutical manufacturers’ activity has 
become an important part of the mechanism for improving the world-wide population health. 
However, the ground for the study was “a pharmaceutical manufacturer phenomenon”: being a part of the system 
focused on vital medicines reproduction, it has become a highly commercialized unit aimed at maximal profit extracting. 
ISSN 2039-2117 (online) 
ISSN 2039-9340 (print) 
        Mediterranean Journal of Social Sciences 
            MCSER Publishing, Rome-Italy 
Vol 6 No 1 
January  2015 
          
 217 
So, the volume of the global pharmaceutical market at final selling prices was estimated more than US $1 trillion and, 
accordingly IMS Health forecasts (leading information-analytical organization in the field of health services), it exceed 
US$1.1 trillion in 2015 (IFPMA, 2013). International Federation of Pharmaceutical Manufacturers & Associations gives its 
vision to the pharmaceutical market progress: its value will approximate to US$ 1.2 trillion in 2017 Figure 1 indicates the 
changes in the global pharmaceutical market’s volume (blue columns) and the growth rates (red curve) for the period 
from 2004 to 2014 (Glumskov, 2007). 
 
 
 
Figure 1. Global pharmaceutical market’s volume and growth rates, 2004-2014 
 
According to the global pharmaceutical market ranks 3rd place by the market capitalization volume with the figure of US 
$1.431 trillion or 5.46% after the bank (US $4.436 trillion or 16.92%) and energy (US $3.832 trillion) sectors (Lin and 
Sokolova, 2012). At the same time it is essential to emphasize FT Global 500 ranking indicator, which illustrates the 
pharmaceutical market commercial nature in a more evident way (Table 1). It claims that 4 positions among the 30 
largest companies in the world (13.3%) are under the pharmaceutical giants from developed countries (named as a “Big 
Pharma” conglomerate (Hetman, 2003): Switzerland (Novartis, Roche) and the USA (Johnson & Johnson, Pfizer 
(Financial Times, 2014). 
 
Table 1. FT Global 500 ranking. Top 30 companies 
 
Ranking, 2013 Ranking, 2012 Company Country of origin Field 
1 1 Apple USA Electronics
2 2 Exxon Mobil USA Oil & Gas
3 13 Berkshire Hathaway USA Insurance
4 3 PetroChina CHINA Oil & Gas
5 11 Wal-Mart Stores USA Retail stores
6 9 General Electric USA Industrial enterprises 
7 4 Microsoft USA Software
8 5 IBM USA Software
9 12 Nestle SWITZERLAND Food
10 10 Chevron USA Oil & Gas
11 6 Industrial & CommercialBank of China CHINA Banks 
12 18 Johnson & Johnson USA Pharmaceuticals 
13 17 Samsung Electronics SOUTH KOREA Electronics
14 8 ChinaMobile HONG KONG Mobile telecommunications 
15 25 Google USA Software
16 16 Procter&Gamble USA Household goods 
17 7 Royal Dutch Shell GB Oil & Gas
18 23 Prfizer USA Pharmaceuticals 
19 14 China Construction Bank CHINA Banks
20 29 Roche SWITZERLAND Pharmaceuticals 
21 15 AT&T USA Telecommunications 
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22 26 HSBC GB Banks
23 19 Wells Fargo USA Banks
24 28 Novartis SWITZERLAND Pharmaceuticals 
25 21 JP Morgan Chase USA Banks
26 24 Coca-Cola USA Beverages
27 30 Toyota Motor JAPAN Automotive industry 
28 20 BHP Billiton AUSTRALIA/ GB Mining
29 40 Anheuser-Busch BELGIUM Beverages
30 32 Oracle USA Software
 
On the one hand, all-time high revenues of pharmaceutical companies may be explained with the need to recoup huge 
research and development expenses (totaling almost US$ 100 billion (IMS Healthcare, 2013) – it takes a company 1-10 
US$ billions and 10-15 years to create and launch a new drug (Glumskov, 2007). On the other one, it may be the so-
called “geographical pool” that is more real state of things in the pharmaceutical market. More simply, it is corporations’ 
conspiracy to deliver high-quality products mainly to countries with high purchasing power of the population in order to 
maximize profits. 
In particular, the world’s leading regions in pharmaceuticals production and consumption accounting for about 80% 
of the world’s medicines market are the United States of America, countries of Western Europe and Japan (Figure 2). 
However, the pharmaceutical sales in the US, Canada, France, Germany, Italy, Spain, UK and Japan decreased by more 
than 2 times for the recent years. Against this background, new emerging pharmaceutical markets, such as India, Brazil, 
China, Korea, Turkey, Russia, Mexico, and Indonesia have been visibly growing (Ternovenko, 2010). It is expected that 
by 2015 the proportion of sales carried out in West-European and developing countries will be equal to 23% of the world’s 
total sales (Figure 2). 
For instance, Indian pharmaceutical industry is one of the most advanced in the world. According to the United 
Nations, in 2008 India got a position in “Top 15” ranking as one of the major medical products exporters with a share of 
1.44%. According to KPMG report, total expenditures including developing, registration and approval of an application of 
a new drug are on average 10% of the similar costs in the US. Another explanation for the active growth of Indian 
pharmaceutical market may also be the global trends, such as aging of the population, and a transition to the prevalence 
cardiovascular and central nervous systems’ diseases. India is expected to become one of the top 10 pharmaceutical 
markets with a volume of US$ 50 billion (Ternovenko, 2010). 
As for the other emerging markets, China may outrun India in a few years. Global corporations are highly 
interested in China because of both abrupt increasing of consumer demand (due to the same reasons as in India), and 
the possibility of low-budget outsourcing. Thus, according to Bain & Company, about 90% of top-managers would prefer 
China than India when placing cheap drugs production. According to DSM Group report, annual increase of retail 
medicines market in China is about 14%, which is 7 times higher than the average rate of 2.1%. However, in this region 
structure of the industry and the degree of legal protection are still poorly developed. As a result, production costs for the 
more advanced stages in China (in particular, clinical trials) are comparable to those in the US and Europe (Industrial 
Review, 2008). Among the other most progressive pharmerging markets double-digit growth rates are also typical for 
national markets of Brazil (+ 17% in 2013), Venezuela (+32% in 2010), Argentina (+26% in 2010), Russia (+10% in 
2013), Turkey, Indonesia and Korea (Ministry of Economic Development of the Russian Federation, 2012).  
 
 
 
Figure 2. Pharmaceuticals sales by regions and countries 
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Another questionable trend in the largest pharmaceutical companies’ activity is policy of enforcement towards local 
companies. For example, in 2010 the Ukrainian divisions of the Franco-British Sanofi-Aventis were fined by antitrust 
authorities for mailing letters criticized the quality of Flenoks (Farmakom company), which was the direct copy-drug of 
Clexane made by Sanofi (Mikhailova, 2010). 
 
2. Methodology 
 
Current trends observed above prove that the global pharmaceutical market is the economy unit with an ambivalent 
nature. In this regard, we should question whether pharmaceutical market solves global health problems or only exists in 
order to maximize profits of the largest drug manufacturers? Herewith, the main goal of the study is searching for the 
answer by means of econometric analyzes (using IBM SPSS Statistics 19). In turn, the main hypothesis is the 
assumption of “geographical pool” existence with related negative consequences. By extension, the global 
pharmaceutical market operates in the interests of developed countries and enterprises hosted there. If so, we deal with 
another confirmation of the global economy uneven and unsustainable development. 
Statistical databases of the World Bank, Organization for Economic Co-operation and Development, World Health 
Organization and information-analytical agencies in the field of health and pharmaceuticals (e.g., IMS Health) for 2011 
were used in the study.  
At the first stage it was presumed that the health services in developing (pharmerging) countries are on emerging 
stages so the public health is low. A spectrum of diseases common for developing countries was revealed mainly while 
studying the industry surveys. It involved infectious and chronic diseases, diabetes mellitus, tuberculosis, malaria and 
AIDS. In particular, accordingly to the experts of Eurasian Bank of Development, the number of people suffering from 
hypertension in developing countries reached the point of 639 million in 2004, but it is expected to be not less than 1 
billion by 2025. In it’s turn, the number of people with diabetes among India, the Middle East and Southeast Asia will 
increase from 84 million in 1995 up to 228 million in 2025 (Eurasian Development Bank, 2013). So, as a dependent 
variable (y) it was taken life expectancy at birth (in number of years). The independent variables (x) were GNI per capita 
(in US dollars); HIV prevalence (in %); the incidence of tuberculosis, respiratory diseases and ischemic heart disease (in 
number of cases per 100 000 persons). According to the analysis it was found out that: 
1. Ischemic heart disease is the main constraint to the life expectancy growth in developed countries; 
2. HIV infection and respiratory diseases are the main constraints to the life expectancy growth in developing 
countries (Nalimov, 2014). 
Results of the analysis may be supported with the conclusion of PURE project, that included 155,245 people aged 
35-70 years from 17 countries with high (Canada, Sweden, the United Arab Emirates, n = 16110), medium (n = 104,260) 
and low (n = 34875) economic level (India, Bangladesh, Pakistan, Zimbabwe). Accordingly to PURE, the highest 
prevalence of risk factors for cardiovascular disease was observed in the “rich countries”, the lowest – in “poor countries”. 
Meanwhile, heart failure were recorded at a frequency of 4.3, 5.1 and 6.4 per 1000 person-years, and the death from 
cardiovascular causes – 0.5, 1.3 and 2.7 per 1000 person-years in countries with high, medium and low economic level, 
respectively. “Rich countries” are notable for early detections and effective treatment of diseases, whereas “poor 
countries” characterized with poor development of health care system (Kanorsky and Mamedov, 2014). 
It is necessary to realize that some diseases are important worldwide, being found in both poor and rich countries, 
and therapies for such diseases have global markets. Others are more specific, with almost their entire market in the 
developing world (for example, malaria). There is almost no investment in the latter category outside of the public sector. 
Without protection in the developing world, there is little interest on the part of firms to invest in therapies for these 
diseases (Lanjouw, 2006). It means that success of treatment in most of the cases about specific diseases in developing 
countries depends on usage of low-budget medicines.  
Herewith, according to the World Health Organization and The Global Fund experts, HIV infection, respiratory 
diseases, malaria and tuberculosis are the main “enemies” of the human health for today. They are ones due to the 
nature of their transmission (infectious nature and high seasonal influence (Holyman, 2005), while ischemic heart disease 
is acquired purely medical case. This means that the population of developing countries is objectively less healthy and 
less protected from infectious influence, and has less incomes and therefore it is in greater need of highly innovative 
drugs. 
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Figure 3. The worldwide structure of drugs consumption in 2011 and 2016 
 
Paradoxically, but the fact is that the lion's share in effective branded drugs production and consumption retain the 
advanced economies, regardless of developing countries needs. Figure 3 indicates that the disproportionate medicine 
distribution has been mentioned above is not changing to its best in the nearest future. Developing countries will face the 
more complicated access to high quality medicines – ratio of branded drugs will decrease from 30% in 2011 to 24% in 
2016. In its turn, generics will be more available – we will observe the trend of low quality drugs growth – from 57% in 
2011 to 65% in 2016 (IMS Healthcare, 2012). 
It is important to make a rigid division between generics and brand drugs. So, branded drugs are innovations 
protected by patent law for 20 years or more. Generics are the drugs that reproduced after patent expiration (WHO 
Technical Report Series, 2005). It is important to note that the lack of health systems in developing countries is 
inadequate or frankly poor state regulation of drugs standardization and circulation. As a result, output of generic drugs 
does not require extensive pre-clinical testing and Good Manufacturing Practices (GMP) compliance. Moreover, a generic 
drug may be essentially different from a brand on the composition of excipients, releasing forms, pharmacokinetic 
parameters and the effectiveness of biotherapeutics (see Interstate Commission for Standardization, Registration and 
Quality Control of Drugs, Medical Devices and Medical Equipment of the Commonwealth of Independent States, 2013). 
Thus, the widespread use of generic drugs on the markets of developing countries may pose a serious threat to the 
health of the population. 
In accordance with the hypothesis of the study at the second stage there were explored causes of such inequality 
by means of regression analysis (IBM SPSS Statistics 19). It was presumed that the causes of high generic drugs 
prevalence in developing countries are lack of research and development (R&D) investment spent by local 
pharmaceutical companies, as well as the state medical care mechanism absence or its underdevelopment. In such 
situation, people in pharmerging countries have to cover all the costs for medical treatment by means of their own 
resource, not relying on a decent state aid. 
A set of indicators characterizing research and development capacity, health potential, rates of mortality and 
effectiveness levels of national pharmaceutical industries was selected in order to conduct a comprehensive hypothesis 
testing. In this way, as a dependent variable (y) it was taken issued share of generic drugs. Independent variables (x) are 
given in Table 2 below. 
 
Table 2. Used independent variables 
VARIABLES 
GNIpc GNI per capita, USD
Ln-GNIpc GNI per capita, logarithm
LIFE Life expectancy at birth, years
SALE Sales of pharmaceuticals per capita, US$
HEpc Health expenditures per capita, US$
HE Out-of-pocket health expenditures, % of all health expenditures
PHEX Export of pharmaceuticals per capita, US$
PHIM Import of pharmaceuticals per capita, US$
GERD R&D expenditures, % of GDP
HDI Human Development Index
TUBER Incidence of tuberculosis, number of cases per 100 000 persons
RESP Respiratory diseases, number of cases per 100 000 persons
ISHMC Ischemic heart disease, number of cases per 100 000 persons
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3. Results 
 
The OLS regression model has shown that R&D expenditures and GNI per capita have the greatest influence on share of 
generic drugs. The most significant variable (at the 5%-level) is also life expectancy at birth. Less significant variables (at 
10%-level) are health expenditures per capita, export of pharmaceuticals per capita and number of ischemic heart 
disease cases per 100 000 persons. The results of the carried econometric analysis are shown in the table 3. 
 
Table 3. The results  
 
Regressors The share of generic drugs in the total drugs consumption (%) (1) (2) (3) (4) (5) (6) 
GNIpc   -,001**(,000) 
-,001***
(,000) 
-,001***
(,000)  
Ln-GNIpc -11,063*(6,128) 
-8,427***
(1,473)    
-7,787*** 
(1,519) 
LIFE -,194(,54)  
-,029
(,513)  
-,534**
(,253)  
SALE -,059(,245)  
-,215
(,243)    
HEpc -,003(,01)  
,007
(,011)    
HE -,193(,132) 
-,199**
(,097) 
-,200
(,128) 
-,202**
(,098) 
-,189*
(,101)  
PHEX ,017(,03)  
,019
(,029)  
,035*
(,020)  
PHIM -,002(,055)  
,017
(,054)    
GERD -12,82**(6,216) 
-10,187**
(4,477) 
-13,832**
(6,049) 
-9,480**
(4,480) 
-15,983***
(4,995) 
-10,072** 
(4,437) 
HDI 47,276(58,602)  
-39,518
(32,288) 
-44,335***
(16,459)   
TUBER ,005(,02)  
,003
(,019)   
,020* 
(011) 
RESP ,001(,03)  
-,001
(,027)    
ISHMC ,049*(,028) 
,057**
(,023) 
,052*
(,029) 
,051**
(,024) 
,043*
(022) 
,040* 
(,021) 
Constant 154,2***(34,6) 
148,237***
(12,617) 
114,045***
(25,071) 
114,193***
(10,143) 
124,824***
(14,423) 
127,228*** 
(12,883) 
Standard 
regression error 15,548 14,747 15,072 14,593 14,293 14,693 
R2 (adjusted R2) ,525 (,421) ,511(,479) 
,553
(,456) 
,528
(,49) 
,535
(,492) 
,494 
(,463) 
N 91 91 88 88 91 91 
Notes:  
* - Significant at the 10% level.  
** - Significant at the 5% level.  
*** - Significant at the 1% level.  
Figures in parentheses are standard errors.  
 
An equation of the OLS regression model is given by (1): 
 (1)  
In accordance with the results of model 5 selected as the basis, share of generic drugs in pharmerging countries 
tends to increase when: 
a. simultaneous increase in pharmaceutical exports and the rate of heart disease (direct dependence) are 
observed; 
b. reducing life expectancy and the proportion of public expenditure spent on research and development, as well 
ISHMCPHEXGERDHELIFEGNIpcY 043.0035.0983.15189.0534.0001.0 ++−−−−=
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as reducing out-of-pocket health expenditures and GNI per capita (inverse dependence) are observed. 
The results presented above enable us to come to a comprehensive conclusion.  
First, negative consequences in predominance of generic drugs have been econometrically substantiated: the 
growth of inefficient medication increases the incidence of cardiovascular diseases, which ultimately has a negative 
impact on life expectancy. 
Second, causes in dominance of generic drugs in the developing markets have been logically set. They are 
government inefficiency in creating incentives for innovative development of pharmaceuticals (It may be explained with 
low R&D costs) and the low purchasing power of the population (due to the inverse dependence between Y and GNI per 
capita). 
And we also may see a paradox in production and consumption of pharmaceuticals among poor countries. It 
means that poorer countries in general contribute little to total world expenditure on drugs for global diseases, but at the 
same time can be a significant major source of demand in some therapy areas. According to Lanjouw (2006), about 46% 
of the world’s population is found in countries representing less than 2% of total expenditure on drugs, for example, for 
cardiovascular disease. It brings us to a conclusion about underdevelopment or even absence of national pharmaceutical 
industries among poorer countries. In this case, theirs huge need for medical drugs should be replenished by means of 
active pharmaceutical import. 
However, the most interesting part of the results is the direct dependence between the ratio of generic drugs and 
the pharmaceutical export. This relationship may be explained by the narrow range of export and import in the scope of 
developing countries: mutual trade of pharmerging economies enhances the effect of low quality generic medicine. At the 
same time, it also means that the world leading corporations producing branded drugs (“Big Pharma”) do not intentionally 
increase the share of innovative medicines in emerging markets (Lanjouw, 2006). There may be a rational explanation: 
being highly commercialized units of the world economy, they choose not to lose money - the main consumers in 
developing countries are moderate income households, which are opposed to the “rich” private and public sectors of 
developed countries. There may be another economically justified interest of developed countries – the lowest possible 
value of the imported goods and raw materials from developing countries. In this respect, advanced economies get the 
benefits from “the idle speed”, not allowing pharmerging countries to grow by means of expensive human capital in the 
form of a healthy workforce (Rudenko and Tilimbaeva, 2013). 
 
4. Concluding Remarks 
 
Thus, extremely heterogeneous emerging markets, ranking at the moment about 20% of the market, are expected to 
become the “giants” that will determine the landscape of the global pharmaceuticals in the near future. The guarantee of 
this trend is their large enough market potential, further development of these markets in the context of health insurance 
implementation and household incomes. Players of the global pharmaceutical market, namely the largest pharmaceutical 
companies, are responding to this trend by increase of its presence and strengthening of its market positions. 
As a mechanism of achieving a balance on the global pharmaceutical market should consist of some stages: 1. a 
consolidation of small national companies from developing countries into the regional pharmaceutical enterprises in order 
to R&D concentration (stage 1); 2. patents buying up (stage 2); 3. the establishment of special customs and tax regimes 
for regionally produced medical drugs (stage 3). 
Herewith, today’s extremely uneven distribution of drugs between “rich” and “poor” countries does not yet allow us 
to speak about the importance of global health problems for all the world community. As a result, the study allows us to 
give an answer to the main question: the global pharmaceutical market is a system that contains all the resources for 
effective solving of global health problems. However, the existence of “Big Pharma” makes us talk about high commercial 
character of the global pharmaceutical market that is now prevailing over the idealistic notion about the healthy planet.  
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